138 related articles for article (PubMed ID: 32154745)
1. Medical Costs and Health Care Utilization Among Self-Insured Members with Carve-In Versus Carve-Out Pharmacy Benefits.
Smith JJ; Qiu Y; Lam SV; Lockwood CM; Pegus C; Gleason PP
J Manag Care Spec Pharm; 2020 Jun; 26(6):766-774. PubMed ID: 32154745
[TBL] [Abstract][Full Text] [Related]
2. Effect of Carving in Pharmacy Benefits on Utilization and Costs.
Parekh N; Papa S; Drnach A; Spiegel L; Huang Y; Manolis C; Good CB
J Manag Care Spec Pharm; 2020 Oct; 26(10):1317-1324. PubMed ID: 32996397
[TBL] [Abstract][Full Text] [Related]
3. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
[TBL] [Abstract][Full Text] [Related]
4. Pharmacy benefit spending on oral chemotherapy drugs.
Curtiss FR
J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
[TBL] [Abstract][Full Text] [Related]
5. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Johnson JT; Neill KK; Davis DA
J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
[TBL] [Abstract][Full Text] [Related]
6. Integrating E-Prescribing and Pharmacy Claims Data for Predictive Modeling: Comparing Costs and Utilization of Health Plan Members Who Fill Their Initial Medications with Those Who Do Not.
Chang HY; Kan HJ; Shermock KM; Alexander GC; Weiner JP; Kharrazi H
J Manag Care Spec Pharm; 2020 Oct; 26(10):1282-1290. PubMed ID: 32996394
[TBL] [Abstract][Full Text] [Related]
7. Reduced medical spending associated with integrated pharmacy benefits.
Lucas E; Liu M; Ouyang J; Vicidomina B; Ford M; Keller BP; Nigam S
Am J Manag Care; 2021 Jul; 27(7):e242-e247. PubMed ID: 34314125
[TBL] [Abstract][Full Text] [Related]
8. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
Cecil WT; Barnes J; Shea T; Coulter SL
J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
[TBL] [Abstract][Full Text] [Related]
9. Health care utilization by children with chronic illnesses: a comparison of medicaid and employer-insured managed care.
Shatin D; Levin R; Ireys HT; Haller V
Pediatrics; 1998 Oct; 102(4):E44. PubMed ID: 9755281
[TBL] [Abstract][Full Text] [Related]
10. Health plan utilization and costs of specialty drugs within 4 chronic conditions.
Gleason PP; Alexander GC; Starner CI; Ritter ST; Van Houten HK; Gunderson BW; Shah ND
J Manag Care Pharm; 2013 Sep; 19(7):542-8. PubMed ID: 23964615
[TBL] [Abstract][Full Text] [Related]
11. Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes.
Garry EM; Schneeweiss S; Eapen S; Petruski-Ivleva N; Cheever E; Murk W; Rajan A; Rassen JA; Gambino D; Jang H; Rubin E; Jan S
J Manag Care Spec Pharm; 2019 Dec; 25(12):1442-1452. PubMed ID: 31778623
[TBL] [Abstract][Full Text] [Related]
12. One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program.
Groeneweg M; Forrester SH; Arnold B; Palazzo L; Zhu W; Yoon P; Scearce T
J Manag Care Spec Pharm; 2018 May; 24(5):458-463. PubMed ID: 29694287
[TBL] [Abstract][Full Text] [Related]
13. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
Yokoyama K; Yang W; Preblick R; Frech-Tamas F
J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
[TBL] [Abstract][Full Text] [Related]
14. Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.
King J; McAdam-Marx C; McCaleb R; Davis D; Bemberg GB; Johnson JT
J Manag Care Spec Pharm; 2019 Jun; 25(6):646-651. PubMed ID: 31134855
[TBL] [Abstract][Full Text] [Related]
15. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
16. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of medication therapy management services for patients with cardiovascular disease in a self-insured employer health plan.
Wittayanukorn S; Westrick SC; Hansen RA; Billor N; Braxton-Lloyd K; Fox BI; Garza KB
J Manag Care Pharm; 2013 Jun; 19(5):385-95. PubMed ID: 23697476
[TBL] [Abstract][Full Text] [Related]
18. Cost of epilepsy-related health care encounters in the United States.
Borghs S; Beaty S; Parekh W; Kalilani L; Boudiaf N; Loewendorf A
J Manag Care Spec Pharm; 2020 Dec; 26(12):1576-1581. PubMed ID: 33103619
[No Abstract] [Full Text] [Related]
19. Drug super spender tsunami: An integrated medical and pharmacy benefits assessment.
Starner CI; Bowen K; Gleason PP
J Manag Care Spec Pharm; 2022 Nov; 28(11):1200-1206. PubMed ID: 36282927
[No Abstract] [Full Text] [Related]
20. Comparison of Specialty Medication Use for Common Chronic Inflammatory Diseases Among Health Exchange and Other Commercially Insured Members.
Chen X; Gautam S; Ruggieri A; Richards T; Devries A; Sylwestrzak G
J Manag Care Spec Pharm; 2018 Jan; 24(1):12-19. PubMed ID: 29290173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
